AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING
The foundation of our solution platform for specialty benefits management is our clinical appropriateness guidelines. AIM Clinical Appropriateness Guidelines for Genetic Testing are developed through a rigorous process integrating evidence-based literature with expert review.
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR HEREDITARY CARDIAC DISEASE
The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Hereditary Cardiac Disease includes testing for inherited arrhythmias and cardiomyopathies.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR HEREDITARY CANCER SUSCEPTIBILITY
The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Hereditary Cancer Susceptibility includes screening for hereditary cancer predisposition syndromes.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR MOLECULAR TESTING OF SOLID AND HEMATOLOGIC TUMORS AND MALIGNANCIES
The testing addressed in the AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies includes genetic testing and gene expression profiling of solid and hematologic tumors for the purpose of diagnosis or for information related to treatment selection, prognosis, or recurrence risks.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR PHARMACOGENETIC TESTING AND GENETIC TESTING FOR THROMBOTIC DISORDERS
The testing addressed in the AIM Clinical Appropriateness Guidelines for Pharmacogenetic Testing and Genetic Testing for Thrombotic Disorders includes genotyping to predict response to certain medications and testing for gene mutations associated with coagulation disorders.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR SINGLE-GENE AND MULTIFACTORIAL CONDITIONS
The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Single-Gene and Multifactorial Conditions includes single-gene testing, multigene diagnostic panels, testing for variants associated with multifactorial conditions, chromosomal microarray analysis, and human leukocyte antigen (HLA) histocompatibility testing.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR WHOLE EXOME AND WHOLE GENOME SEQUENCING
The testing addressed in the AIM Clinical Appropriateness Guidelines for Whole Exome and Whole Genome Sequencing includes the diagnostic use of whole exome and genome sequencing in the evaluation of rare disease.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR REPRODUCTIVE CARRIER SCREENING AND PRENATAL DIAGNOSIS
The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis includes carrier testing for familial mutations and common and ethnic genetic diseases; preimplantation screening and diagnosis; prenatal screening and diagnosis; and testing for recurrent pregnancy loss and infertility.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All rights reserved.
CLINICAL GUIDELINES ACCESS
Accessing Clinical Guidelines and Cancer Treatment Pathways
By clicking on the “I accept” button below, I acknowledge I accept the following terms and conditions when accessing and using the Clinical Guidelines and Cancer Treatment Pathways:
AIM Specialty Health® (AIM) has developed proprietary Clinical Guidelines and Cancer Treatment Pathways (together with any updates, referred to collectively as the “Guidelines and Pathways”). The Guidelines and Pathways are designed to evaluate and direct the appropriate utilization of certain health care services. They are based on data from peer-reviewed scientific literature, from criteria developed by specialty societies, and from guidelines adopted by other health care organizations. Access to these Guidelines and Pathways is being provided for informational purposes only. Although AIM has a process for updating its Guidelines and Pathways on a regular basis, due to the rapidly evolving nature of medicine, these Guidelines and Pathways may not reflect the most current evidence on a particular service or treatment.
The Guidelines and Pathways are protected by copyright of AIM as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Guidelines and Pathways and that you are expressly prohibited from selling, assigning, leasing, licensing, reproducing, or distributing the Guidelines and Pathways unless authorized in writing by AIM.
The Guidelines and Pathways do not constitute medical advice and/or medical care and do not guarantee results or outcomes. The Guidelines and Pathways are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines or Pathways is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The Guidelines and Pathways do not address coverage, benefit, or other plan specific issues.
The Guidelines and Pathways are provided “as is” without warranty of any kind, either expressed or implied. AIM disclaims all responsibility for any consequences or liability attributable or related to any use, nonuse, or interpretation of information contained in the Guidelines.
About the AIM Clinical Appropriateness Guidelines for Genetic Testing
The AIM Clinical Appropriateness Guidelines for Genetic Testing (with any updates, referred to as the “Genetic Testing Guidelines”) were developed by and used with permission from Informed Medical Decisions, Inc.
The Genetic Testing Guidelines are protected by copyright of Informed Medical Decisions, Inc., as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Genetic Testing Guidelines and that you are expressly prohibited from selling, assigning, leasing, licensing, reproducing, or distributing the Genetic Testing Guidelines unless authorized in writing by Informed Medical Decisions.
AIM and Informed Medical Decisions, Inc., disclaim all responsibility for any consequences or liability attributable or related to any use, nonuse, or interpretation of information contained in the Genetic Testing Guidelines.